Augmenting HER2 Inhibition by Targeting PI3K – Lessons From Metastatic Brain Cancer

24 Jun 2021 10AM
Augmenting HER2 Inhibition by Targeting PI3K – Lessons From Metastatic Brain Cancer

PI3K is part of the signaling cascade for HER2 and therefore drugs modulating both targets are potentially synergistic•

PI3K inhibition has been explored as a means to overcome resistance to HER2-directed therapies• Paxalisib, a brain-penetrant PI3K inhibitor, is under investigation for HER2+ breast cancer brain metastases

https://her2-targeted-therapies.com/whats-on/agenda/day-two/